<DOC>
	<DOCNO>NCT01318083</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety alogliptin , daily ( QD ) combine Sulfonylurea take QD twice daily ( BID ) type 2 diabetic patient uncontrolled blood glucose .</brief_summary>
	<brief_title>Efficacy Safety Alogliptin Used Combination With Sulfonylurea Participants With Type 2 Diabetes Japan</brief_title>
	<detailed_description>Both insulin hyposecretion insulin-resistance consider involved development type 2 diabetes mellitus . Takeda develop SYR-322 ( alogliptin ) improvement glycemic control patient type 2 diabetes mellitus . Alogliptin inhibitor dipeptidyl peptidase IV ( DPP-IV ) enzyme . DPP-IV think primarily responsible degradation 2 peptide hormone release response nutrient ingestion . It expect inhibition DPP-IV improve glycemic control patient type 2 diabetes . The present study plan evaluate efficacy safety alogliptin add-on sulfonylurea type 2 diabetic patient uncontrolled blood glucose despite treatment sulfonylurea well diet exercise therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1 . Had take sulfonylurea least 4 week prior initiation observation period ( Week 12 ) . 2 . Had take glimepiride stable dose regimen ( 1 , 2 , 3 4 mg/day , twice daily morning morning evening , meal ) least 12 week prior initiation treatment period ( Week 0 ) . 3 . Had glycosylated hemoglobin ( HbA1c ) 7.0 % 10.0 % 8 week initiation observation period ( Week 4 ) . 4 . Had HbA1c difference 4 week initiation observation period ( Week 8 ) 8 week initiation observation period ( Week 4 ) within 10.0 % * value 4 week initiation observation period ( Week 8 ) ( *rounded first decimal place ) . 5 . Was receive specific diet exercise ( ) therapies observation period . 1 . Had take diabetic medication glimepiride within 12 week initiation treatment period ( Week 0 ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Diabetes Mellitus - Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>